Abstract
Objective:
This study investigated the association between Helicobacter pylori (H. pylori) infection and the expression of CD163+ and CD86+ tumor-associated macrophages (TAMs) in colorectal adenoma (CRA) and colorectal cancer (CRC) tissues.
Methods:
Immunohistochemistry (IHC) was used to evaluate the expression of CD163+ and CD86+ TAMs isolated from colorectal tissues, Multiplex immunofluorescence (mIF) co-staining was employed to identify CD68+CD163+ and CD68+CD86+ TAMs, and the 14C-urea breath test (UBT) was used to detect H.pylori infection.
Results:
The progression of colorectal lesions was significantly associated with increased expression of CD163+ and CD86+ TAMs, as well as H.pylori infection (all P < 0.05). The expression of CD163+ and CD86+ TAMs were positively correlated with each other and with the severity of colorectal lesions (all P < 0.001). Patients with H.pylori infection exhibited significantly higher expression of both TAM subsets compared with non-infected individuals (all P < 0.05). Multiple linear regression analysis showed that in colorectal adenomas measuring ≥ 1 cm, expression of CD163+ and CD86+ TAM was significantly greater than in adenomas <1 cm (P < 0.05), Expression of CD163+ TAM was notably higher in obese patients with CRC. Multiplex immunofluorescence (mIF) quantification revealed significantly increased densities of both CD68+CD86+ and CD68+CD163+ TAMs, and a higher CD68+CD163+/CD68+CD86+ ratio in colorectal cancer (CRC) (all P < 0.001).
Conclusions:
The expression of CD68+CD163+ and CD68+CD86+ TAMs change dynamically with the progression of colorectal lesions. These changes are influenced by H.pylori infection, adenoma size, tumor differentiation, and patient metabolic status.
1 Introduction
Colorectal cancer (CRC) is a common malignant tumor of the digestive system. According to global cancer statistics in 2020, the incidence and mortality of CRC both rank third among all malignant tumors (). The pathogenesis of CRC is associated with multiple factors, including genetic predisposition, environmental influences, lifestyle, and the gut microbiota. Notably, dysbiosis of the gut microbiota or infection with certain bacteria, such as Helicobacterpylori (H. pylori), can increase the risk of colorectal tumors (). In addition, Gut microbiota linked to obesity is implicated in the pathogenesis of colorectal cancer (). This is an important issue that warrants considerable attention.
Colorectal adenomas (CRA) mainly include two major categories: conventional adenomas(CAs) and sessile serrated adenomas (SSAs). CAs are further subdivided into tubular adenomas, villous adenomas, and tubulovillous (mixed) adenomas, each with distinct histological characteristics and malignant potential. SSAs are characterized by a unique serrated glandular architecture and a higher rate of malignant transformation, distinguishing them from CAs. Both types of adenomas carry a risk of malignant progression () and are recognized as precancerous lesions. Timely detection and intervention can reduce the risk of CRC development. Although colorectal cancer (CRC) treatment employs a multidisciplinary, multimodal integrated strategy (), a proportion of patients present with advanced disease at diagnosis, having missed the optimal window for radical treatment. Consequently, their overall prognosis is significantly worse than that of early-stage patients (Stage I patients exhibit a > 90% 5-year survival rate) (). Thus, there is an urgent need to identify novel tumor biomarkers that can predict tumor progression and serve as potential therapeutic targets.
The tumor microenvironment (TME) is a complex and dynamic ecosystem with high heterogeneity, Macrophages within the TME, known as tumor-associated macrophages (TAMs), are important immune effector cells primarily derived from peripheral blood monocytes and tissue-resident macrophages. TAMs consist mainly of two subsets, M1 and M2 (). The M1 phenotype generally inhibits tumor growth, whereas the M2 phenotype promotes tumor growth. The balance between both subsets determines the nature of the immune response in the TME.
Cell surface markers of TAMs primarily include CD68 (pan-macrophage), CD86 (M1-like macrophage markers), and CD163 (M2-like macrophage markers) (, ). In the TME of CRC, the polarization state of TAMs is associated with cancer-specific survival, and M1-like/M2-like TAMs phenotypes exhibit distinct prognostic implications (). Targeting TAMs as a therapeutic strategy has already become an effective approach to inhibit tumor progression (). Nonetheless, the mechanisms by which TAMs evolve within the TME during the malignant progression of CRA are still not completely understood.
H.pylori infection can promote tumor development by influencing TAMs polarization in the TME. For example, sit. et al. () found that H.pylori phospholipase A regulates macrophage autophagy and apoptosis via the TNFR1-mediated p38 signaling pathway. Lu et al. () reported that interactions between reactive oxygen species and hypoxia-inducible factor-1α modulate H.pylori–induced macrophage polarization through the Akt/mTOR pathway. In addition, H.pylori infection can upregulate the expression of indoleamine 2,3-dioxygenase in macrophages, thereby inducing M2-like polarization (). M2-like TAMs secrete various growth factors, enabling tumor cells to evade immune surveillance and elimination. Therefore, further investigation of the impact of H.pylori infection on TAMs polarization in CRA and CRC tissues is warranted.
In this study, we analyzed the expression of CD163+ and CD86+ TAMs in CRA and CRC tissues and examined their correlation with H.pylori infection, with the aim of providingreferences for clinical research.
2 Materials and methods
2.1 Study population
This study included patients diagnosed with CRA or CRC at the Affiliated Hospital of West Anhui Health Vocational College between January and December 2023. A total of 109 patients were enrolled, and clinical data and colorectal tissue specimens were collected. Among these, 61 patients had CRA, including 36 with CAs and 25 with SSAs. Among the 36 patients with CAs, 18 were tubular adenomas and 18 were tubulovillous adenomas. The study also included 29 patients with CRC and 19 individuals with normal colorectal mucosa who served as control. The normal control group comprised asymptomatic volunteers. Inclusion required: (i) endoscopically normal colonic mucosa with histopathological confirmation, (ii) no antibiotics 3 months/PPIs 1 month pre-enrollment, (iii) verified H. pylori-negative status. This study employed the urea breath test (UBT) as the sole diagnostic criterion for H.pylori infection. While UBT offers standardized operational advantages, the lack of orthogonal verification methods (e.g., histopathology, stool antigen testing, or serology) may lead to misclassification of infection status, thereby introducing unquantified classification bias.
2.1.1 Inclusion criteria
The following inclusion criteria were applied to patients for this study: (i) tissue specimens with a definitive pathological diagnosis of either a CAs, a SSA, or CRC. The diagnostic criteria for SSA were crypt distortion and dilation with basal expansion forming a serrated architecture that extends along the muscularis mucosae, resulting in an inverted T-shaped or L-shaped configuration (); (ii) availability of complete clinical and pathological data were available for each patient, including sex, age, tumor stage, tumor differentiation, lymph node metastasis status, and tumor location; (iii) H.pylori testing was performed in accordance with consensus guidelines. All subjects confirmed no history of eradication therapy and documented discontinuation of antibiotics/bismuth agents (≥ 4 weeks) as well as PPIs/acid suppressants (≥ 14 days) prior to sampling, A 14C-urea breath test (UBT) value ≥ 100 decays per minute (dpm) is defined as the positive diagnostic threshold for active H.pylori infection; and (iv) informed consent provided for the collection and use of their clinical data.
2.1.2 Exclusion criteria
The following patients were excluded: (i) patients with severe cardiovascular, respiratory, or hematological diseases; (ii) those who had received any non-surgical treatments (such as radiotherapy, chemotherapy, targeted therapy, or immunotherapy); and (iii) patients with incomplete clinical or pathological data. The study was approved by the ethics committee of the Affiliated Hospital of West Anhui Health Vocational College (Approval No. LAEY-2022-017).
2.2 Main reagents and equipment
The following reagents and equipment were used in this study: mouse monoclonal anti-CD163 antibody (10D6, ma5-11458, Invitrogen, Waltham, MA02451, USA); rabbit monoclonal anti-CD86 antibody (EP1158-37, ab269587, Abcam, Cambridge, UK); rabbit Polyclonal anti-CD68 antibody (GB113150, Servicebio, Wuhan, China); rabbit Polyclonal anti-CD163 antibody (GB113152, Servicebio, Wuhan, China); rabbit Polyclonal anti-CD86 antibody (GB115630, Servicebio, Wuhan, China); secondary antibodies and DAB chromogenic kits (Biomiky, Biosharp, and Servicebio, respectively). 14C-urea breath test detector (Haidwei HUBT-20A2); and Haidwei disposable gas collection cards. Positive control tissues: (i) CD68+ and CD163+ macrophages: Human spleen (red pulp region); (ii) CD86+ macrophages: Human tonsil (germinal center). For validation, three randomly selected cases per cohort were analyzed by: (i) IHC quantification via H-score (range 0-300); (ii) Dual-color mIF confirming cellular co-expression in lesional tissue.
2.3 Immunohistochemistry
Specimens were fixed in formalin, embedded in paraffin, and sectioned into 3 μm-thick slices, Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0) at 98 °8 for 20 minutes, Primary antibodies against CD163 (1:50) and CD86 (1:100) were applied after dilution, and slides were incubated at 4 °C, Secondary antibody incubation was conducted at room temperature for 15 min, followed by DAB staining for 4 minutes, Hematoxylin counterstaining and gradient alcohol dehydration were performed, and sections were mounted using neutral resin. Yellow-brown or tan granular staining was interpreted as positive expression. Two independent researchers evaluated the samples, For each slide, five randomly selected non-overlapping fields were analyzed at 200× magnification, The integrated optical density (IOD) of positive staining was quantified using ImageJ software, The mean IOD was calculated and used as the final result for each sample (, ).
2.4 Multiplex immunofluorescence
Twenty formalin-fixed, paraffin-embedded (FFPE) colorectal tissue samples were analyzed across three groups: normal mucosa (n=4), The CRA cohort included 10 cases: 5 CAs (3 tubular, 2 tubulovillous) and 5 SSA, and CRC (n=6). For each specimen, two consecutive sections were prepared and subjected to immunofluorescence staining: one for dual detection ofCD68+CD163+ TAMs, and the other for CD68+CD86+ TAMs. Double-positive macrophage density was quantified by dual-channel co-localization analysis (Pearson’s coefficient ≥ 0.6) in ImageJ. For each specimen, three anatomical zones were defined: Central zone (tumor core ± 1 mm), Marginal zone (invasive front ± 500 μm),Adjacent mucosal zone (≥ 2 mm from the margin). Cell counting primarily focused on stromal and combined zones, using hexagonal grid systematic sampling with 9 non-overlapping fields per zone (200 x magnification). Field distribution satisfied spatial uniformity testing (K-S p > 0.05). Data were normalized to cells per square millimeter (cells/mm²). Observer Agreement: Two pathologists independently counted 100% of specimens in a blinded manner. Intraclass Correlation Coefficient (ICC) = 0.92 (95% CI 0.88-0.95), Bland-Altman analysis: Mean bias + 1.5 cells/mm² (95% LoA-6.2 to 9.3), Results exceeded the prespecified reliability threshold (ICC ≥ 0.85).
2.5 Statistical analysis
All statistical analyses were conducted using SPSS v.27.0 software. Continuous variables conformed to normal distribution (Shapiro-Wilk p > 0.05), presented as [M ± SD], One-way ANOVA was employed to analyze intergroup differences (effect size ηp2), If results were significant (p < 0.05), Tukey HSD method was applied for pairwise comparisons (controlling FWER at α = 0.05). Continuous variables failing normality tests (Shapiro-Wilk p < 0.05) were summarized by medians and IQRs, defined as [Q1, Q3], Group differences were assessed using the Kruskal-Wallis H-test for three or more groups, Upon significance (p<0.05), pairwise localization employed Dunn-Bonferroni-adjusted (DB-adjusted) post hoc procedures, Comparisons between exactly two independent groups utilized the Mann-Whitney U test (MWU test). Categorical variables are presented as n (%), Intergroup comparisons were performed using Pearson’s χ²-test or Fisher’s exact test based on expected frequencies. Correlations between variables were assessed using Spearman’s rank correlation coefficient. A P-value < 0.05 was considered statistically significant. Multiple linear regression analysis was performed to identify independent factors associated with CD163+ and CD86+ TAMs expression. The regression model was specified as follows:
where Y represents the expression level of CD163+ or CD86+ TAMs (as integrated optical density, IOD), β0 is the intercept, β1 to β1 are regression coefficients for the independent variables X1 to X1, and ϵ is the error term. The model assumptions were checked using residual plots and the Shapiro-Wilk test. No severe multicollinearity was detected (all variance inflation factors < 5).
Prior to constructing the multivariate linear regression model, we first performed univariate analyses to screen clinical variables associated with TAMs expression. Covariates ultimately included in the model comprised variables with P-values < 0.05 in the univariate analyses, as well as important potential confounders identified based on clinical knowledge and expert judgment. Accordingly, factors such as adenoma size, adenoma number, obesity, tumor differentiation grade, lymph node metastasis, TNM stage, and H. pylori infection were collectively included in the final model. This strategy ensured that the model incorporated both statistical associations from the data and biological plausibility, thereby enabling a more accurate estimation of the independent associations between these factors and TAMs expression.
Given the relatively small sample size in the CRC group, the precision and statistical power of the model may be limited. This issue was addressed by using bidirectional stepwise regression to optimize variable selection and minimize overfitting, with results presented with 95% confidence intervals to reflect uncertainty.
3 Results
3.1 Expression of CD163+ TAMs, CD86+ TAMs, and H. pylori infection
CD163+ and CD86+ TAMs were primarily located in the stromal matrix and appeared as brownish-yellow or tan granules. Their expression increased progressively with colorectal malignancy, from normal tissue to CRC, indicating a potential immunological role in tumor progression (Figures 1A, B).
Figure 1
Statistical analysis revealed significant differences in the expression of CD163+ and CD86+ TAMs among the normal, CAs, SSA, and CRC groups (all P < 0.05) (Figures 1C, D). DB-adjusted for pairwise comparison showed significantly higher expression in CRC than in tissues from CAs and SSA groups, and higher levels in CAs and SSA than tissues in the normal group (all P < 0.05). No significant difference was found between the CAs and SSA groups (P > 0.05). The overall trend in tissue expression was as follows: normal < CRA < CRC (P < 0.05) (Table 1).
Table 1
| CRA(n=61) | ||||||
|---|---|---|---|---|---|---|
| Variables | Normal (n=19) | CAs (n=36) | SSA (n=25) | CRC (n=29) | Statistic | P |
| CD163,M (Q1,Q3) | 2066.45 (1492.80,3769.28) | 8195.20 (5009.03,14448.74)# | 6134.79 (4148.07,9337.56)# | 19614.60 (7182.47,22899.10)#△ | χ²=51.913⋆ | <0.001 |
| CD86,M (Q1,Q3) | 2227.46 (1590.13,2721.17) | 6139.86 (4491.34,8963.26)# | 4261.13 (3055.10,5898.95)# | 11644.53 (6618.20,15188.14)#△ | χ²=61.431⋆ | <0.001 |
| H.pylori,n(%) | χ²=33.755 | <0.001 | ||||
| Uninfected | 18 (94.74) | 18 (50)# | 14 (56.00)# | 3 (10.34)#△ | ||
| Infected | 1 (5.26) | 18 (50)# | 11 (44.00)# | 26 (89.66)#△ | ||
Expression of CD163+/CD86+ TAMs and H. pylori infection rates across groups.
⋆: Kruskal-Wallis test; M: Median; Q1: 1st Quartile; Q3: 3rd Quartile. DB-adjusted/Pearson’s χ² test: #P < 0.05 vs. normal, △P < 0.05 vs. CRA.
H.pylori infection rates also differed significantly among groups (P < 0.05). Bonferroni-corrected partitioned chi-square method for Pairwise comparisons indicated a higher rate in CRC compared with CAs and SSA, and higher in CAs and SSA compared with the normal group (all P < 0.05). There was no significant difference between CAs and SSA (P > 0.05). The overall trend in the infection rate was CRC > CRA > Normal (P < 0.05) (Table 1).
3.2 Association between CD163+/CD86+ TAMs, H. pylori infection, and colorectal malignancy
CD163+ and CD86+ TAMs were significantly more abundant in H.pylori-positive patients compared with those without infection (P < 0.001; Figure 2A). A strong positive correlation was found between CD163+ and CD86+ expression (Spearman’s ρ = 0.813, P < 0.001; Figure 2B). Both markers were also positively correlated with CRC progression (CD163+: ρ = 0.561, P < 0.001; CD86+: ρ = 0.587, P < 0.001; Figures 2C, D).
Figure 2
3.3 Expression in CRA patients by clinical characteristics
In the CRA group, patients with adenomas ≥1 cm in diameter had higher expression of CD163+ and CD86+ TAMs than those with smaller adenomas (P < 0.05). Similarly, patients with multiple adenomas showed higher expression than those with single adenomas (P < 0.05). Patients who were H.pylori-positive also had higher marker expression than non-infected individuals (P < 0.05) (Table 2).
Table 2
| Variable | N (%) | CD163,M (Q1,Q3) | Statistic | P | CD86,M (Q1,Q3) | Statistic | P |
|---|---|---|---|---|---|---|---|
| Total | 61 (100) | 7065.96 (4483.53,10672.70) | 5601.69 (3684.24,8045.12) | ||||
| Sex | Z=-0.131 | 0.896 | Z=0.000 | 1.000 | |||
| Male | 34 (55.74) | 7702.38 (4773.17,9427.82) | 5580.89 (3780.79,7007.27) | ||||
| Female | 27 (44.26) | 7015.93 (4477.27,13379.70) | 5632.93 (3331.30,8710.58) | ||||
| Age | Z=-0.247 | 0.805 | Z=-0.261 | 0.794 | |||
| < 60 | 34 (55.74) | 7253.25 (4128.22,12354.00) | 5580.89 (3427.60,8784.28) | ||||
| ≥ 60 | 27 (44.26) | 7055.07 (5791.30,9578.44) | 5632.93 (4482.40,7086.22) | ||||
| Site | Z=-0.073 | 0.942 | Z=-0.054 | 0.957 | |||
| Rectum | 12 (19.67) | 7442.74 (3873.30,12539.05) | 4997.73 (3783.96,7924.32) | ||||
| Colon | 49 (80.33) | 7065.96 (4647.59,10658.54) | 5601.69 (3503.18,8464.31) | ||||
| Diameter | Z=-6.022 | <.001 | Z=-6.311 | <.001 | |||
| <1 cm | 32 (52.46) | 4565.56 (3645.91,6652.60) | 3732.52 (2921.31,4746.60) | ||||
| ≥1 cm | 29 (47.54) | 11626.15 (8781.84,15454.57) | 8464.31 (6173.92,9480.48) | ||||
| Number | Z=-6.115 | <.001 | Z=-5.690 | <.001 | |||
| Solitary | 25 (40.98) | 4128.22 (3139.36,4926.54) | 3503.18 (2746.34,4362.52) | ||||
| Multiple | 36 (59.02) | 9578.44 (7702.38,14577.13) | 7046.79 (5738.68,9268.61) | ||||
| Obesity | Z=-2.388 | 0.017 | Z=-1.288 | .198 | |||
| yes | 28(45.90) | 8528.66(7026.26,11142.35) | 5990.63(4371.46,8569.32) | ||||
| no | 33(54.10) | 5764.89(3699.20,10672.70) | 5138.11(3494.33,7803.52) | ||||
| H.pylori | Z=-5.416 | <.001 | Z=-5.705 | <.001 | |||
| Infected | 29(47.54) | 10672.70 (8194.00,15454.57) | 7803.52 (6038.08,9480.48) | ||||
| Uninfected | 32(52.46) | 4565.56 (3645.91,6864.03) | 3732.52 (2921.31,4746.60) |
Expression of CD163+/CD86+ TAMs and H. pylori infection across CRA patient subgroups.
Z: Mann-Whitney test; M: Median; Q1: 1st Quartile; Q3: 3rd Quartile.
3.4 Expression in CRC patients by clinical characteristics
In CRC patients, CD163+ TAM expression was significantly higher in stages III–IV compared with I–II (P < 0.05), in those with lymph node metastases (P < 0.05), and in patients with low tumor differentiation (P < 0.05). CD86+ TAM expression was lower in patients at stages III–IV and in those with metastases or low differentiation (all P < 0.05). Both markers were expressed at higher levels in H.pylori-infected patients (P < 0.05) (Table 3).
Table 3
| Variable | n (%) | CD163,M (Q1,Q3) | Statistic | P | CD86,M (Q1,Q3) | Statistic | P |
|---|---|---|---|---|---|---|---|
| Total | 29 (100) | 19614.60 (7182.47,22899.10) | 11644.53 (6618.20,15188.14) | ||||
| Sex | Z=-1.594 | 0.117 | Z=-1.373 | 0.180 | |||
| Male | 12 (41.38) | 14434.26 (4841.20,22105.68) | 12642.80 (10927.33,16746.85) | ||||
| Female | 17 (58.62) | 20303.61 (13682.83,26651.32) | 10396.24 (5969.45,13086.00) | ||||
| Age group | Z=-0.330 | 0.764 | Z=-0.236 | 0.835 | |||
| < 60 | 9 (31.03) | 16639.37 (13682.83,21559.32) | 11822.28 (7094.63,13572.10) | ||||
| ≥ 60 | 20 (68.97) | 20291.80 (6723.18,23286.39) | 11337.34 (6584.85,16746.85) | ||||
| Site | Z=-0.094 | 0.945 | Z=-0.754 | 0.472 | |||
| Rectum | 9 (31.03) | 16390.73 (7182.47,28215.57) | 11644.53 (5969.45,13572.10) | ||||
| Colon | 20 (68.97) | 19959.11 (9320.94,22804.17) | 11528.45 (7019.85,16746.85) | ||||
| TNM stage | Z=-2.575 | 0.009 | Z=-2.095 | 0.037 | |||
| I-II | 14 (48.28) | 7100.39 (4841.94,21559.32) | 15107.70 (10824.51,18771.47) | ||||
| III-IV | 15 (51.72) | 21645.88 (18287.86,25162.50) | 10396.24 (6260.48,11767.89) | ||||
| LN metastasis | Z=-2.182 | 0.029 | Z=-2.182 | 0.029 | |||
| Negative | 15 (51.72) | 7182.47 (4971.80,22229.21) | 15027.25 (11083.95,18538.51) | ||||
| Positive | 14 (48.28) | 21307.44(16961.12,23673.68) | 8745.44 (5969.45,11713.50) | ||||
| Histology | Z=-3.822 | <0.001 | Z=-2.956 | 0.002 | |||
| Low | 22 (75.86) | 21602.60 (16639.37,26551.32) | 10713.19 (6181.94,12294.42) | ||||
| Middle -High | 7 (24.14) | 4841.94 (4749.17,6059.98) | 18771.47 (15938.83,19515.05) | ||||
| Obesity | Z=-4.099 | <0.001 | Z=-2.147 | 0.032 | |||
| yes | 21(72.41) | 21645.88(16961.12,26651.32) | 11030.14(6551.50,12294.42) | ||||
| no | 8(27.59) | 4971.80(4749.17,6641.10) | 18538.51(12198.31,195515.05) | ||||
| H.pylori | Z=-2.077 | 0.037 | Z=-2.005 | 0.045 | |||
| Infected | 26(89.66) | 20636.31 (12229.14,23673.68) | 11767.89 (6945.07,17212.47) | ||||
| Uninfected | 3(10.34) | 6263.88 (5402.55,8943.73) | 5869.24 (5261.12,8346.88) |
Expression of CD163+/CD86+ TAMs and H. pylori infection in CRC patient subgroups.
Z: Mann-Whitney test; M: Median; Q1: 1st Quartile; Q3: 3rd Quartile.
3.5 mIF analysis confirmed significant enrichment of TAMs in CRC tissues
mIF-based quantitative analysis revealed significantly higher counts of CD68+CD163+ and CD68+CD86+ TAMs and an elevated CD68+CD163+/CD68+CD86+ TAMs ratio in the CRC cohort (n=6) compared to the CAS cohort (n=10) and normal controls(n=4). The overall trend in tissue expression was as follows: CRC > CRA > Normal (all P < 0.001). (Figures 3, 4).
Figure 3
Figure 4
3.6 Multiple linear regression in CRA and CRC groups
Multiple linear regression was performed using CD163+ and CD86+ TAMs expression as dependent variables. For the CRA group, independent variables included adenoma size, number, obesity, age, sex, site, and H.pylori infection status. For the CRC group, independent variables included age, sex, site, tumor differentiation, lymph node metastasis, TNM stage, obesity, and H.pylori infection status. The results indicated that expression levels were significantly associated with adenoma diameter in CRA, and with differentiation, obesity, and H.pylori infection in patients with CRC (Table 4).
Table 4
| Group | Variables | β | S.e | T | P | β (95%CI) |
|---|---|---|---|---|---|---|
| CRA-CD86 | Diameter | |||||
| < 1cm | Reference | |||||
| ≥1 cm | 4488.870 | 505.200 | 8.885 | <.001 | 4488.870 (3477.967 ~ 5499.773) | |
| CRA-CD163 | Diameter | |||||
| <1 cm | Reference | |||||
| ≥1 cm | 7545.441 | 984.454 | 7.665 | <.001 | 7545.441 (5575.552 ~ 9515.329) | |
| CRC-CD86 | H.pylori | |||||
| Uninfected | Reference | |||||
| Infected | 6228.716 | 2493.190 | 2.498 | 0.019 | 6228.716 (1103.890 ~ 11353.542) | |
| Histology | ||||||
| Low | Reference | |||||
| Middle -High | 7991.376 | 1774.363 | 4.504 | <.001 | 7991.376 (4344.122 ~ 11638.631) | |
| CRC-CD163 | Obesity | |||||
| no | Reference | |||||
| yes | 16405.198 | 2206.201 | 7.436 | <.001 | 16405.198 (11878.446 ~ 20931.949) |
Multiple linear regression analysis of factors associated with CD163+/CD86+ TAM expression in CRA and CRC patients.
Stepwise (bidirectional) regression method.
4 Discussion
The transition from CRA to CRC is a prolonged process that requires several decades. Therefore, early detection and resection of precancerous lesions are critical for preventing progression of CRC. TAMs have been implicated in the pathogenesis of H.pylori-related gastric malignancies (). Wei et al. demonstrated that H.pylori can activate the JAK1/STAT1 signaling pathway in macrophages, leading to CCL3 secretion and subsequent gastric mucosal damage (). Furthermore, H.pylori promotes gastric carcinogenesis by enhancing interleukin (IL)-6-mediated autocrine and paracrine loops between macrophages and gastric epithelial cells (). Recent studies have also linked H.pylori infection to an elevated risk of CRC (–). Notably, CRC incidence decreases significantly following H.pylori eradication (). Ralser et al. found that Helicobacter pylori infection accelerates tumorigenesis, concomitant with depletion of regulatory T (Treg) cells and pro-inflammatory T cells, goblet cell deficiency, and STAT3 pathway activation (). Luo et al. further reported that H.pylori-induced temperate phage expansion and microbiota interactions may contribute to CRC pathogenesis (). Our study found that H.pylori infection rates were highest in CRC patients, followed by those with CRA, and lowest in the normal group, suggesting a positive correlation between infection and disease severity. This supports the hypothesis that H. pylori may play a role in CRC development.
CD163 is predominantly expressed on monocytes and tissue macrophages, Prior studies indicate that CD163+ TAMs may induce regulatory T cell expansion via IL-10/TGF-sl thereby exhausting effector T cells. Numerous studies have reported that CD163 is increased in different cancers and is associated with poor prognosis due to its tumor-promoting functions (–). For example, Lira et al. demonstrated that M2-like macrophages facilitate cervical cancer progression via the STAT3/NF-κB pathway (), whereas Ito et al. showed that in CRC, M2-like macrophages enhance their resistance to oxidative stress through the Nrf2/HO-1 axis, promoting survival in the TME (). CD86 is an immunophenotype associated with antitumor immune modulation, Evidence suggests that CD86+ TAMs may inhibit CD8+ T cell activation through PD-L1 co-expression. Teng et al. reported that CASC19 transferred from M1-like macrophages to colon cancer cells via exosomes inhibited tumor cell proliferation and migration by targeting miR-410-3p (). A reduction in M1-like macrophages infiltration has also been associated with poor prognosis in right-sided CRC patients (). This study revealed progressively elevated CD163+ and CD86+ TAMs levels in colorectal tissues: normal mucosa < CRA < CRC, suggesting their potential involvement in immune modulation during tumor progression. These findings offer insights for developing potential immunotherapeutic and prognostic strategies in CRC.
Several studies have suggested a link between H.pylori infection and macrophage polarization. Peng et al. found that H.pylori induced indoleamine 2,3-dioxygenase expression and M2-like polarization (). Lu et al. reported that in all stages of gastric lesions, patients who are H.pylori-positive showed higher expression of CD86 and CD206 compared with H. pylori-negative individuals (). our study found elevated levels of CD163+ and CD86+ TAMs in H.pylori-infected patients. This suggests that H.pylori may recruit TAMs through specific pathways, with testable hypotheses including: (i) H.pylori drives Treg-mediated immunosuppression by recruiting CD163+ TAMs, verifiable via mIF assessing spatial co-localization between CCL19+ epithelial cells and CD163+ TAMs; (ii) CD86+ TAMs in CRC patients lose antigen-presenting capacity and undergo transformation into a ‘pseudo-activated’ state, testable through flow-sorted CD86+ TAMs co-cultured with CD8+ T cells followed by PD-1 expression analysis. Thus, elevated CD163+CD86+ TAM levels may associate with T-cell dysfunction, though their causality and H.pylori’s direct role require further validation.
Zhang et al. found that CD163+ macrophages promote polyp progression in pediatric patients by inhibiting T-cell responses via TGF-β production (). Peyravian et al. showed that CD86 expression positively correlated with dysplasia in polyps (). Our univariate analysis indicated that patients with adenomas ≥1 cm or multiple adenomas exhibited significantly higher expression of both CD163+ and CD86+ TAMs. Multivariate regression further confirmed this relationship: CD163+ TAMs (β = 7545.441, 95% CI: 5575.552 ~ 9515.329) and CD86+ TAMs (β = 4488.870, 95% CI: 3477.967 ~ 5499.773) were significantly increased in patients with larger adenomas. Our univariate analysis found that in CRC patients, lower differentiation, advanced TNM stage, and lymph node metastasis were associated with higher expression of CD163+ TAM and lower expression of CD86+ TAM. Consistent with previous studies (37, 38). These results suggest that TAMs expression reflect disease severity and may contribute to assess malignancy risk. The M2-like/M1-like macrophages ratio is a useful prognostic indicator, Fadhil et al. reported higher M2-like/M1-like macrophages ratios in breast cancer patients than in controls (39), and Parekh et al. found similar results in advanced oral submucous fibrosis and squamous cell carcinoma (40). Our study further demonstrated a progressive increase in the CD68+CD163+/CD68+CD86+ ratio from normal tissue through CRA to CRC, highlighting the role of macrophage phenotypic switching and imbalance in TME homeostasis during carcinogenesis. Additionally, the body mass index is a known risk factor for CRC incidence and mortality (41). Obesity may enhance macrophage activation by suppressing miR-192 expression (42). In CRC groups, patients with obesity exhibited higher CD163+ TAM expression. Multivariate regression confirmed this association in CRC (β = 16405.198, 95% CI: 11878.446 ~ 20931.949), suggesting that obesity-induced TME changes may contribute to CD163+ TAM enrichment and tumorigenesis.
This study also has several limitations:(i) The single-center, cross-sectional design precludes determination of the temporal sequence and causal relationships between H.pylori infection and TAMs;(ii) The relatively small sample size in the CRC cohort may compromise the precision and statistical power of the multivariate regression model. Although stepwise regression was employed to mitigate overfitting, the findings should be interpreted with caution and validated in larger cohorts;(iii) Elevated H.pylori prevalence (~90%) in the CRC cohort risks overestimating its effects on TAMs polarization, compromising findings’ generalizability;(iv) Reliance on UBT as the sole detection method may introduce non-differential misclassification, potentially attenuating effect sizes. Due to sample size limitations, we could not quantify bias severity by excluding high-risk misclassified subsets. Future studies should incorporate H.pylori stool antigen testing to comprehensively enhance diagnostic accuracy; (v) the coverage of macrophage marker panels was limited; (vi) residual confounding factors were not fully controlled, in addition, multiple comparisons introduced statistical inference risks.
Future studies should: (i) Validate and refine the TAMs differentiation model in expanded prospective cohorts stratified by H.pylori infection status; (ii) Establish a multimodal H.pylori detection framework integrating stool antigen testing, PCR genotyping, and culture verification; (iii) Spatially resolve TAM-tumor cell crosstalk networks under H.pylori-positive conditions using transcriptomics; (iv) Verify H.pylori-mediated TAMs regulation via flow-sorted subpopulations and organoid co-cultures targeting candidate pathways identified in ().
In conclusion, this study found that CD163+ and CD86+ TAMs are significantly increased in CRC and are associated with H. pylori infection. Their expression correlates with lesion severity, indicating a potential role in CRC pathogenesis. However, further studies are warranted to elucidate their exact mechanisms in colorectal tumor development and progression.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving humans were approved by Affiliated Hospital of West Anhui Health Vocational College (Approval No. LAEY-2022-017). The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.
Author contributions
WMW: Funding acquisition, Validation, Formal Analysis, Resources, Conceptualization, Project administration, Writing – review & editing, Data curation, Methodology, Software, Writing – original draft, Supervision, Investigation, Visualization. YCZ: Writing – review & editing, Investigation, Conceptualization, Writing – original draft, Software, Funding acquisition, Supervision, Resources, Visualization, Project administration, Data curation, Validation, Methodology, Formal Analysis. JW: Funding acquisition, Resources, Writing – review & editing, Software, Visualization, Writing – original draft, Formal Analysis, Project administration, Conceptualization, Validation, Data curation, Investigation, Methodology, Supervision. YYZ: Writing – original draft, Formal Analysis, Writing – review & editing, Resources, Funding acquisition, Visualization, Project administration, Methodology, Supervision, Data curation, Conceptualization, Software, Validation, Investigation.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. This study was supported by the Joint Funds for the Innovation of Science and Technology in Fujian Province (NO.2020Y9119).
Acknowledgments
The authors confirm that no acknowledgments are applicable to this work.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
H. pylori, Helicobacter pylori; TAMs, tumor-associated macrophages; CRA, colorectal adenoma; CRC, colorectal cancer; IHC, immunohistochemistry; mIF, multiplex immunofluorescence; UBT, 14C-urea breath test; SSAs, serrated adenomas; CAs, conventional adenomas; TME, tumor microenvironment; IOD, integrated optical density; FFPE, paraffin-embedded; ICC, intraclass correlation coefficient; DB-adjusted, Dunn-Bonferroni-adjusted; MWU test, Mann-Whitney U test.
References
1
SungHFerlayJSiegelRLLaversanneMSoerjomataramIJemalAet al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. doi: 10.3322/caac.21660
2
ShahSCCamargoMCLammMBustamanteRRoumieCLWilsonOet al. Impact of helicobacter pylori infection and treatment on colorectal cancer in a large,Nationwide cohort. J Clin Oncol. (2024) 42:1881–89. doi: 10.1200/JCO.23.00703
3
KangXNgSKLiuCLinYZhouYKwongTNYet al. Altered gut microbiota of obesity subjects promotes colorectal carcinogenesis in mice. EBioMedicine. (2023) 93:104670. doi: 10.1016/j.ebiom.2023.104670
4
ErichsenRBaronJAHamilton-DutoitSJSnoverDCTorlakovicEEPedersenLet al. Increased risk of colorectal cancer development among patients with serrated polyps. Gastroenterology. (2016) 150:895–902. doi: 10.1053/j.gastro.2015.11.046
5
GhadimiMRödelCHofheinzRFlebbeHGradeM. Multimodal treatment of rectal cancer. Dtsch Arztebl Int. (2022) 119:570–80. doi: 10.3238/arztebl.m2022.0254
6
SiegelRLWagleNSCercekASmithRAJemalA. Colorectal cancer statistics, 2023. CA Cancer J Clin. (2023) 73:233–54. doi: 10.3322/caac.21772
7
KadomotoSIzumiKMizokamiA. Macrophage polarity and disease control. Int J Mol Sci. (2022) 23:144. doi: 10.3390/ijms23010144
8
ZhangSChuahSJLaiRCHuiJHPLimSKTohWSet al. MSC exosomes mediate cartilage repair by enhancing proliferation,attenuating apoptosis and modulating immune reactivity. Biomaterials. (2018) 156:16–27. doi: 10.1016/j.biomaterials.2017.11.028
9
FangJOuQWuBLiSWuMQiuJet al. TcpC Inhibits M1 but Promotes M2 Macrophage Polarization via Regulation of the MAPK/NF-κB and Akt/STAT6 Pathways in Urinary Tract Infection. Cells. (2022) 11:2674. doi: 10.3390/cells11172674
10
VäyrynenJPHarukiKLauMCVäyrynenSAZhongRCostaADet al. The prognostic role of macrophage polarization in the colorectal cancer microenvironment. Cancer Immunol Res. (2021) 9:8–19. doi: 10.1158/2326-6066.CIR-20-0527
11
ZhangXLiSMalikIDoMHJiLChouCet al. Reprogramming tumour-associated macrophages to outcompete cancer cells. Nature. (2023) 619:616–23. doi: 10.1038/s41586-023-06256-5
12
SitWYChengMLChenTJChenCJChenBNHuangDJet al. *Helicobacter pylori*PldA modulates TNFR1-mediated p38 signaling pathways to regulate macrophage responses for its survival. Gut Microbes. (2024) 16:2409924. doi: 10.1080/19490976.2024.2409924
13
LuYRongJLaiYTaoLYuanXGShuXet al. The Degree of Helicobacter pylori Infection Affects the State of Macrophage Polarization through Crosstalk between ROS and HIF-1α. Oxid Med Cell Longevity. (2020) 2020:5281795.16p. doi: 10.1155/2020/5281795
14
PengRXuCZhangLLiuXPengDChenXet al. M2 macrophages participate in ILC2 activation induced by Helicobacter pylori infection. Gut Microbes. (2024) 16:2347025. doi: 10.1080/19490976.2024.2347025
15
MurakamiTSakamotoNNagaharaA. Clinicopathological features, diagnosis, and treatment of sessile serrated adenoma/polyp with dysplasia/carcinoma. J Gastroenterol Hepatol. (2019) 34:1685–95. doi: 10.1111/jgh.14752
16
WuJLiGLiuJSunWLiuJZouGet al. Utility of shear wave–based ultrasound elastography in chronic kidney disease and related pathological quantitative analysis. Eur Radiol. (2023) 33:5625–33. doi: 10.1007/s00330-023-09507-1
17
LiuCLiangGDengZTanJZhengQLyuFJet al. The upregulation of COX2 in humanDegenerated nucleus pulposus: the association of inflammationwith intervertebral disc degeneration. Mediators Inflammation. (2021) 2021:2933199. doi: 10.1155/2021/2933199
18
LiuMZhangLZhouQWangYSunQRenXet al. The distinct impact of TAM infiltration on the prognosis of patients with cardia and non-cardia gastric cancer and its association with H. pylori infection. Front Oncol. (2021) 11:737061. doi: 10.3389/fonc.2021.737061
19
WeiYFLiXZhaoMRLiuSMinLZhuSTet al. Helicobacter pylori disrupts gastric mucosal homeostasis by stimulating macrophages to secrete CCL3. Cell Commun Signaling. (2024) 22:263. doi: 10.1186/s12964-024-01627-5
20
YuBDe VosDGuoXPengSXieWPeppelenboschMPet al. IL-6 facilitatescross-talk between epithelial cells and tumor-associated macrophages in Helicobacter pylori-linked gastric carcinogenesis. Neoplasia. (2024) 50:100981. doi: 10.1016/j.neo.2024.100981
21
NamJHHongCWKimBCShinARyuKHParkBJet al. Helicobacter pylori infection is an independent risk factor for colonic adenomatous neoplasms. Cancer Causes Control. (2016) 28:107–15. doi: 10.1007/s10552-016-0839-x
22
ShenLBianRWangWZhaoJ. Association of Helicobacter pylori infection with colorectal adenoma in the Chinese urban population:A cross-sectional study. Microbial Pathogen. (2021) 158:105111. doi: 10.1016/j.micpath.2021.105111
23
ButtJVargaMGBlotWJTerasLVisvanathanKLe MarchandLet al. Serological response to Helicobacter pylori proteins associate with risk of colorectal cancer among diverse populations in the United States. Gastroenterology. (2019) 156:175–186.e2. doi: 10.1053/j.gastro.2018.09.054
24
SonnenbergAGentaRM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol. (2013) 108:208–15. doi: 10.1038/ajg.2012.407
25
GuoCGZhangFJiangFWangLChenYZhangWet al. Long-term effect of Helicobacter pylori eradication on colorectal cancer incidences. Ther Adv Gastroenterol. (2023) 16:1–11. doi: 10.1177/17562848231170943
26
RalserADietlAJaroschSEngelsbergerVWanischAJanssenKPet al. Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature. Gut. (2023) 72:1258–70. doi: 10.1136/gutjnl-2022-328075
27
LuoSRuJMirzaeiMKXueJPengXRalserAet al. Gut virome profiling identifies an association between temperate phages and colorectal cancer promoted by Helicobacter pylori infection. Gut Microbes. (2023) 15:2257291. doi: 10.1080/19490976.2023.2257291
28
DawoudMMAiadHAESKasemNSEl KhoulyEABAl-SharakyDR. Is overexpression of CD163 and CD47 in tumour cells of breast carcinoma implicated in the recruitment oftumour-associated macrophages (TAMs) in tumour microenvironment? immunohistochemical prognostic study. J Immunoassay Immunochem. (2024) 45:342–61. doi: 10.1080/15321819.2024.2358879
29
XueTYanKCaiYSunJChenZChenXet al. Prognostic significance of CD163+tumor-associated macrophages in colorectal cancer. World J Surg Oncol. (2021) 19:186. doi: 10.1186/s12957-021-02299-y
30
TudorFMarijićBBabarovićETudorFMarijicBHadžisejdicIet al. Significance of PD-L1 and tumor microenvironment in laryngeal squamous cell cancer. Cancers. (2024) 16:2645. doi: 10.3390/cancers16152645
31
LiraGADe AzevedoFMDos Santos LinsIGDe Lima MarquesILLiraGAEichCet al. High M2-TAM infiltration and STAT3/NF-κB signaling pathway asa predictive factor for tumor progression and death in cervical cancer. Cancers. (2024) 16:2496. doi: 10.3390/cancers16142496
32
ItoMMimuraKNakajimaSOkayamaHSaitoKNakajimaTet al. M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 inthe colorectal cancer tumor microenvironment. Cancer Immunol Immunother. (2023) 72:2233–44. doi: 10.1007/s00262-023-03406-6
33
TengSGeJYangYCuiZMinLLiWet al. M1 macrophages deliver CASC19 via exosomes to inhibit the proliferation and migration of colon cancercells. Med Oncol. (2024) 41:286. doi: 10.1007/s12032-024-02444-z
34
LimDMKangJWooSYChoiHSKwonMKimJet al. Risk stratification of patients with right-sided colorectal cancer based on the tumor-infiltrating M1 macrophage. Am J Cancer Res. (2022) 12:5532–51. doi: 10.7150/ajcr.5551
35
ZhangSLiXZhuLMingSWangHXieJet al. CD163+macrophages suppress T cell response by producing TGF-β in pediatric colorectal polyps. Int Immunopharmacol. (2021) 96:107644. doi: 10.1016/j.intimp.2021.107644
36
PeyravianNGharibEMoradiAMobahatMTarbanPAzimzadehPet al. Evaluating the expression level of co-stimulatory molecules CD80 and CD86 in different types of colon polyps. Curr Res Transl Med. (2017) 66:19–25. doi: 10.1016/j.retram.2017.11.003
37
InagakiKKunishoSTakigawaHYugeROkaSTanakaSet al. Role of tumor-associated macrophages at the invasive front in human colorectal cancer progression. Cancer Sci. (2021) 112:2692–704. doi: 10.1111/cas.14940
38
KouYLiZSunQYangSWangYHuCet al. Prognostic value and predictive biomarkers of phenotypes of tumour-associated macrophages in colorectal cancer. Scand J Immunol. (2022) 95:e13137. doi: 10.1111/sji.13137
39
FadhilMMAbdul-RasheedOFAl-NaqqashM. Clinical value of peripheral blood M2/M1 like monocyte ratio in the diagnosis of breast cancer and the differentiation between benign and Malignant breast tumors. Acta Biochim Pol. (2019) 66:437–43. doi: 10.18388/abp.2019_2855
40
ParekhNMDesaiRSBansalSPShirsatPMPrasadPS. The role of M1(CD11c) and M2 (CD163) interplay in the pathogenesis of oral submucous fibrosis and its Malignant transformation: An immunohistochemical analysis. Cytokine. (2024) 183:156742. doi: 10.1016/j.cyto.2024.156742
41
ParagomiPZhangZAbeSKIslamMRRahmanMSSaitoEet al. Body mass index and risk of colorectal cancer incidence and mortality in asia. JAMA Netw Open. (2024) 7:e2429494. doi: 10.1001/jamanetworkopen.2024.29494
42
WuSTangWLiuLWeiKTangYMaJet al. Obesity-induced downregulation of miR-192 exacerbates lipopolysaccharide-induced acute lung injury by promoting macrophage activation. Cell Mol Biol Lett. (2024) 29:36. doi: 10.1186/s11658-024-00558-w
Summary
Keywords
CD163, CD86, colorectal adenomas, colorectal cancer, Helicobacter pylori
Citation
Wang W, Zhu Y, Zhu Y and Wang J (2025) Tumor-associated macrophage expression in colorectal adenomas and carcinomas: relationship to Helicobacter pylori infection. Front. Oncol. 15:1649619. doi: 10.3389/fonc.2025.1649619
Received
18 June 2025
Revised
28 October 2025
Accepted
04 November 2025
Published
28 November 2025
Volume
15 - 2025
Edited by
Nadia Judith Jacobo-Herrera, National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico
Reviewed by
Markus Gerhard, Technical University of Munich, Germany
Layla Simon, Finis Terrae University, Chile
Updates
Copyright
© 2025 Wang, Zhu, Zhu and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yueyong Zhu, zhuyueyong@fjmu.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.